Literature DB >> 28091859

Cancer Genetic Counselors' Current Practices and Attitudes Related to the Use of Tumor Profiling.

LeAnne Noelle Goedde1, Nathan W Stupiansky2, Melissa Lah3, Kimberly A Quaid3, Stephanie Cohen4.   

Abstract

Tumor profiling (TP) is primarily used to identify driver mutations within a tumor for treatment purposes, but it may also identify germline mutations. Current involvement of cancer genetic counselors (GCs) in the TP process is not clear. Members of the National Society of Genetic Counselors Cancer Special Interest Group were invited to participate in a confidential, web-based survey to characterize current practices and attitudes related to the use of TP. Of 105 useable responses, 86.7% of GCs reported their institutions were using TP, although only 6.7% did this routinely. Although 63.7% reported personal involvement in the process, largely with result interpretation and follow-up germline testing, 69.7% reported seeing fewer than 5 patients for this reason and 97.9% desired further education on this topic. Work and regional setting were not predictors of involvement with TP; however, GCs in the academic setting were less aware of who obtains consent (p = 0.001). GCs reported they were not often utilized as a resource regarding TP. Overall, GCs believed TP is beneficial in identifying hereditary cancer syndromes, although most reported finding a germline mutation in <10% of cases. This study provides a snapshot of current GC involvement with TP, and documents the desire by GCs for additional education on tumor profiling.

Entities:  

Keywords:  Cancer genetics; Genetic counseling; Genetic counselor; Incidental findings; Precision oncology; Tumor genomic profiling

Mesh:

Year:  2017        PMID: 28091859     DOI: 10.1007/s10897-017-0065-z

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  14 in total

Review 1.  The genetic basis for cancer treatment decisions.

Authors:  Janet E Dancey; Philippe L Bedard; Nicole Onetto; Thomas J Hudson
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.

Authors:  Jennifer J Johnston; Wendy S Rubinstein; Flavia M Facio; David Ng; Larry N Singh; Jamie K Teer; James C Mullikin; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

3.  Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing.

Authors:  P M Boland; K Ruth; J M Matro; K L Rainey; C Y Fang; Y N Wong; M B Daly; M J Hall
Journal:  Clin Genet       Date:  2015-01-22       Impact factor: 4.438

Review 4.  Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology.

Authors:  Martijn P Lolkema; Christa G Gadellaa-van Hooijdonk; Annelien L Bredenoord; Peter Kapitein; Nancy Roach; Edwin Cuppen; Nine V Knoers; Emile E Voest
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

5.  Traditional roles in a non-traditional setting: genetic counseling in precision oncology.

Authors:  Jessica N Everett; Shanna L Gustafson; Victoria M Raymond
Journal:  J Genet Couns       Date:  2014-03-01       Impact factor: 2.537

6.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.

Authors:  Mark E Robson; Angela R Bradbury; Banu Arun; Susan M Domchek; James M Ford; Heather L Hampel; Stephen M Lipkin; Sapna Syngal; Dana S Wollins; Noralane M Lindor
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 7.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 8.  The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?

Authors:  Rishi Jain; Michelle J Savage; Andrea D Forman; Reetu Mukherji; Michael J Hall
Journal:  J Natl Compr Canc Netw       Date:  2016-06       Impact factor: 11.908

9.  The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of uncertain significance.

Authors:  Elizabeth Varga; Elizabeth C Chao; Nicholas D Yeager
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

Review 10.  Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

Authors:  Bettina Meiser; Kathy Tucker; Michael Friedlander; Kristine Barlow-Stewart; Elizabeth Lobb; Christobel Saunders; Gillian Mitchell
Journal:  Breast Cancer Res       Date:  2008-11-28       Impact factor: 6.466

View more
  4 in total

1.  Physician Experiences and Understanding of Genomic Sequencing in Oncology.

Authors:  Caroline M Weipert; Kerry A Ryan; Jessica N Everett; Beverly M Yashar; Arul M Chinnaiyan; J Scott Roberts; Raymond De Vries; Brian J Zikmund-Fisher; Victoria M Raymond
Journal:  J Genet Couns       Date:  2017-08-24       Impact factor: 2.537

2.  Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial.

Authors:  Alice Chen; Keith Flaherty; Peter J O'Dwyer; Bruce Giantonio; Donna M Marinucci; Ju-Whei Lee; Elda Railey; Mary Lou Smith; Carol White; Barbara Conley
Journal:  JCO Precis Oncol       Date:  2020-10-05

3.  Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.

Authors:  E Ileana Dumbrava; L Brusco; M Daniels; C Wathoo; K Shaw; K Lu; X Zheng; L Strong; J Litton; B Arun; A K Eterovic; M Routbort; K Patel; Yuan Qi; S Piha-Paul; V Subbiah; D Hong; J Rodon; S Kopetz; J Mendelsohn; G B Mills; K Chen; F Meric-Bernstam
Journal:  JCO Precis Oncol       Date:  2019-04-11

4.  Additional germline findings from a tumor profiling program.

Authors:  Neda Stjepanovic; Tracy L Stockley; Philippe L Bedard; Jeanna M McCuaig; Melyssa Aronson; Spring Holter; Kara Semotiuk; Natasha B Leighl; Raymond Jang; Monika K Krzyzanowska; Amit M Oza; Abha Gupta; Christine Elser; Lailah Ahmed; Lisa Wang; Suzanne Kamel-Reid; Lillian L Siu; Raymond H Kim
Journal:  BMC Med Genomics       Date:  2018-08-09       Impact factor: 3.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.